The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology

Cancer Treatment Reviews

Volumn 33, Issue 4, 2007, Pages 369-380

  Harmsen, S ^a   Meijerman, I ^a   Beijnen, J H ^a,b   Schellens, J H M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Anticancer drugs; CYP3A4; Drug drug interactions; Induction; Nuclear receptors; Oncology; PXR

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANALGESIC AGENT; ANASTROZOLE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DOCETAXEL; ERLOTINIB; GLUCURONOSYLTRANSFERASE 1A1; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; IFOSFAMIDE; IMATINIB; IRINOTECAN; KETOCONAZOLE; LETROZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PREGNANE X RECEPTOR; RIFAMPICIN; TAMOXIFEN; UNINDEXED DRUG; VITAMIN D RECEPTOR;

AREA UNDER THE CURVE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME INDUCTION; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; RECEPTOR UPREGULATION; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 34248561199     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.02.003     Document Type: Review

References (101)

1. Kuhlmann J., and Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Safety 24 (2001) 715-725
2. Beijnen J.H., and Schellens J.H. Drug interactions in oncology. Lancet Oncol 5 (2004) 489-496
3. Kohler G.I., Bode-Boger S.M., Busse R., Hoopmann M., Welte T., and Boger R.H. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38 (2000) 504-513
4. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 (2004) 2489-2503
5. Meijerman I., Beijnen J.H., and Schellens J.H. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 11 (2006) 742-752
6. McLeod H.L.E., and Oral W.E. Cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 5 (1999) 2669-2671
7. Engels F.K., Ten Tije A.J., Baker S.D., Lee C.K., Loos W.J., Vulto A.G., et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75 (2004) 448-454
8. Malingre M.M., Beijnen J.H., and Schellens J.H. Oral delivery of taxanes. Invest New Drugs 19 (2001) 155-162
9. Product info of erlotinib. http://www.gene.com/gene/products/information/oncology/tarceva/insert.jsp.
10. Clarke L., and Waxman D.J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49 (1989) 2344-2350
11. de Jonge M.E., Huitema A.D., van Dam S.M., Beijnen J.H., and Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 55 (2005) 507-510
12. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92 (1998) 73-82
13. Baes M., Gulick T., Choi H.S., Martinoli M.G., Simha D., and Moore D.D. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 14 (1994) 1544-1552
14. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., and Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102 (1998) 1016-1023
15. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7 (2001) 584-590
16. Dai G., and Wan Y.J. Animal models of xenobiotic receptors. Curr Drug Metab 6 (2005) 341-355
17. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., and Kliewer S.A. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62 (2002) 638-646
18. Jackson J.P., Ferguson S.S., Negishi M., and Goldstein J.A. Phenytoin induction of the Cyp2c37 gene is mediated by the constitutive androstane receptor. Drug Metab Dispos (2006)
19. Chen C., Staudinger J.L., and Klaassen C.D. Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab Dispos 31 (2003) 908-915
20. Jones S.A., Moore L.B., Shenk J.L., Wisely G.B., Hamilton G.A., McKee D.D., et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14 (2000) 27-39
21. Xie W., Barwick J.L., Downes M., Blumberg B., Simon C.M., Nelson M.C., et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406 (2000) 435-439
22. Bauer B., Yang X., Hartz A.M., Olson E.R., Zhao R., Kalvass J.C., et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70 (2006) 1212-1219
23. Goodwin B., Moore L.B., Stoltz C.M., McKee D.D., and Kliewer S.A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60 (2001) 427-431
24. Ferguson S.S., Chen Y., LeCluyse E.L., Negishi M., and Goldstein J.A. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 68 (2005) 747-757
25. Chen Y., Ferguson S.S., Negishi M., and Goldstein J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308 (2004) 495-501
26. Sonoda J., Xie W., Rosenfeld J.M., Barwick J.L., Guzelian P.S., and Evans R.M. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci USA 99 (2002) 13801-13806
27. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P., Negishi Y., Bottroff B.S., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100 (2003) 4150-4155
28. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002) 2908-2915
29. Lamba J.K., Lamba V., Yasuda K., Lin Y.S., Assem M., Thompson E., et al. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther 311 (2004) 811-821
30. Honkakoski P., Zelko I., Sueyoshi T., and Negishi M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18 (1998) 5652-5658
31. Kawamoto T., Sueyoshi T., Zelko I., Moore R., Washburn K., and Negishi M. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19 (1999) 6318-6322
32. Yoshinari K., Kobayashi K., Moore R., Kawamoto T., and Negishi M. Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 548 (2003) 17-20
33. Maglich J.M., Parks D.J., Moore L.B., Collins J.L., Goodwin B., Billin A.N., et al. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278 (2003) 17277-17283
34. Huang W., Zhang J., Chua S.S., Qatanani M., Han Y., Granata R., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100 (2003) 4156-4161
35. Ferguson S.S., LeCluyse E.L., Negishi M., and Goldstein J.A. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 62 (2002) 737-746
36. Chen Y., Ferguson S.S., Negishi M., and Goldstein J.A. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64 (2003) 316-324
37. Goodwin B., Hodgson E., D'Costa D.J., Robertson G.R., and Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62 (2002) 359-365
38. Sugatani J., Kojima H., Ueda A., Kakizaki S., Yoshinari K., Gong Q.H., et al. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33 (2001) 1232-1238
39. Saini S.P., Sonoda J., Xu L., Toma D., Uppal H., Mu Y., et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 65 (2004) 292-300
40. Burk O., Arnold K.A., Geick A., Tegude H., and Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386 (2005) 503-513
41. Watkins R.E., Davis-Searles P.R., Lambert M.H., and Redinbo M.R. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331 (2003) 815-828
42. Collingwood T.N., Urnov F.D., and Wolffe A.P. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23 (1999) 255-275
43. Sueyoshi T., and Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41 (2001) 123-143
44. Xie W., Barwick J.L., Simon C.M., Pierce A.M., Safe S., Blumberg B., et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 14 (2000) 3014-3023
45. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 60 (2001) 1399-1406
46. Drocourt L., Ourlin J.C., Pascussi J.M., Maurel P., and Vilarem M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277 (2002) 25125-25132
47. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Lown K.S., and Watkins P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 51 (1997) 741-754
48. Adachi R., Shulman A.I., Yamamoto K., Shimomura I., Yamada S., Mangelsdorf D.J., et al. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol 18 (2004) 43-52
49. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002) 1313-1316
50. Gnerre C., Blattler S., Kaufmann M.R., Looser R., and Meyer U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14 (2004) 635-645
51. Handschin C., Podvinec M., Amherd R., Looser R., Ourlin J.C., and Meyer U.A. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J Biol Chem 277 (2002) 29561-29567
52. Jung D., Mangelsdorf D.J., and Meyer U.A. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 281 (2006) 19081-19091
53. Pascussi J.M., Drocourt L., Fabre J.M., Maurel P., and Vilarem M.J. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58 (2000) 361-372
54. Pascussi J.M., Drocourt L., Gerbal-Chaloin S., Fabre J.M., Maurel P., and Vilarem M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268 (2001) 6346-6358
55. Jover R., Bort R., Gomez-Lechon M.J., and Castell J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 33 (2001) 668-675
56. Chen Y., Kissling G., Negishi M., and Goldstein J.A. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 314 (2005) 1125-1133
57. Brandon E.F., Raap C.D., Meijerman I., Beijnen J.H., and Schellens J.H. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189 (2003) 233-246
58. Ogg M.S., Gray T.J., and Gibson G.G. Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur J Drug Metab Pharmacokinet 22 (1997) 311-313
59. Roymans D., Annaert P., Van Houdt J., Weygers A., Noukens J., Sensenhauser C., et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 33 (2005) 1004-1016
60. Luo G., Guenthner T., Gan L.S., and Humphreys W.G. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5 (2004) 483-505
61. Persson K.P., Ekehed S., Otter C., Lutz E.S., McPheat J., Masimirembwa C.M., et al. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res 23 (2006) 56-69
62. Kobayashi K., Yamanaka Y., Iwazaki N., Nakajo I., Hosokawa M., Negishi M., et al. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 33 (2005) 924-929
63. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29 (2001) 242-251
64. Gardner-Stephen D., Heydel J.M., Goyal A., Lu Y., Xie W., Lindblom T., et al. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32 (2004) 340-347
65. Payen L., Sparfel L., Courtois A., Vernhet L., Guillouzo A., and Fardel O. The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol Toxicol 18 (2002) 221-233
66. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79 (2006) 206-217
67. O'Reilly R.A. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med 81 (1974) 337-340
68. Zelunka E.J. Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient. Pharmacotherapy 22 (2002) 387-390
69. Chen J., and Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 5 (2006) 3
70. Kerbusch T., Jansen R.L., Mathot R.A., Huitema A.D., Jansen M., van Rijswijk R.E., et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 70 (2001) 132-141
71. Bolton A.E., Peng B., Hubert M., Krebs-Brown A., Capdeville R., Keller U., et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53 (2004) 102-106
72. Niemi M., Backman J.T., Fromm M.F., Neuvonen P.J., and Kivisto K.T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42 (2003) 819-850
73. Smith P., Bullock J.M., Booker B.M., Haas C.E., Berenson C.S., and Jusko W.J. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24 (2004) 1508-1514
74. Mathijssen R.H., Verweij J., de Bruijn P., Loos W.J., and Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94 (2002) 1247-1249
75. Innocenti F., Undevia S.D., Ramirez J., Mani S., Schilsky R.L., Vogelzang N.J., et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther 76 (2004) 490-502
76. Murry D.J., Cherrick I., Salama V., Berg S., Bernstein M., Kuttesch N., et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 24 (2002) 130-133
77. Chang S.M., Kuhn J.G., Rizzo J., Robins H.I., Schold Jr. S.C., Spence A.M., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16 (1998) 2188-2194
78. Zamboni W.C., Gajjar A.J., Heideman R.L., Beijnen J.H., Rosing H., Houghton P.J., et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4 (1998) 783-789
79. Relling M.V., Pui C.H., Sandlund J.T., Rivera G.K., Hancock M.L., Boyett J.M., et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356 (2000) 285-290
80. Baker D.K., Relling M.V., Pui C.H., Christensen M.L., Evans W.E., and Rodman J.H. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10 (1992) 311-315
81. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
82. Nallani S.C., Goodwin B., Maglich J.M., Buckley D.J., Buckley A.R., and Desai P.B. Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos 31 (2003) 681-684
83. Kostrubsky V.E., Ramachandran V., Venkataramanan R., Dorko K., Esplen J.E., Zhang S., et al. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27 (1999) 887-894
84. Kostrubsky V.E., Lewis L.D., Strom S.C., Wood S.G., Schuetz E.G., Schuetz J.D., et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 355 (1998) 131-136
85. Nallani S.C., Goodwin B., Buckley A.R., Buckley D.J., and Desai P.B. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 54 (2004) 219-229
86. Mani S., Huang H., Sundarababu S., Liu W., Kalpana G., Smith A.B., et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res 11 (2005) 6359-6369
87. Crewe H.K., Ellis S.W., Lennard M.S., and Tucker G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53 (1997) 171-178
88. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J., et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 30 (2002) 608-612
89. Dowsett M., Cuzick J., Howell A., and Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 85 (2001) 317-324
90. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53 (1993) 5629-5637
91. Chang T.K., Yu L., Maurel P., and Waxman D.J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57 (1997) 1946-1954
92. Lindley C., Hamilton G., McCune J.S., Faucette S., Shord S.S., Hawke R.L., et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30 (2002) 814-822
93. Mensah-Osman E. Ecteinascidin-743 is a potent inhibitor of P450 3A4 enzyme and accumulates cytoplasmic PXR to inhibit transcription of P450 3A4 and MDR1: Implications for the enhancement of cytotoxicity to chemotherapeutic agents in osteosarcoma. 2005 ASCO Annual Meeting; 2005.
94. Kanzaki A., Takebayashi Y., Ren X.Q., Miyashita H., Mori S., Akiyama S., et al. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1 (2002) 1327-1334
95. Lamba V., Yasuda K., Lamba J.K., Assem M., Davila J., Strom S., et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199 (2004) 251-265
96. Jiao D.Y.M., Hankin J.H., Low S.H., and Chung F.L. Total isothiocyanate contents in cooked vegetables frequently consumed in singapore. J Agric Food Chem 46 (1998) 1055-1058
97. Zhou C., Poulton E.J., Grun F., Bammler T.K., Blumberg B., Thummel K.E., et al. The dietary isothiocyanate, sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor (SXR). Mol Pharmacol (2006)
98. Takeshita A., Taguchi M., Koibuchi N., and Ozawa Y. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277 (2002) 32453-32458
99. Huang H., Wang H., Sinz M., Zoeckler M., Staudinger J., Redinbo M.R., et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26 (2007) 258-268
100. Loose D.S., Stover E.P., and Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 72 (1983) 404-408
101. Duret C., Daujat-Chavanieu M., Pascussi J.M., Pichard-Garcia L., Balaguer P., Fabre J.M., et al. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol 70 (2006) 329-339